Roivant Sciences Other accrued liabilities decreased by 94.3% to $583.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.1%, from $1.17M to $583.00K. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows a downward trend with a -29.1% CAGR.
Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.
This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...
Commonly used as a catch-all for short-term liabilities; varies by industry and business model.
current_liabilities_other_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.30M | $10.66M | $12.44M | $10.86M | $4.08M | $5.05M | $14.31M | $15.08M | $19.89M | $8.60M | $31.34M | $13.94M | $27.53M | $8.92M | $3.61M | $1.17M | $4.19M | $1.48M | $10.24M | $583.00K |
| QoQ Change | — | +28.4% | +16.7% | -12.7% | -62.4% | +23.6% | +183.4% | +5.4% | +31.9% | -56.8% | +264.5% | -55.5% | +97.4% | -67.6% | -59.5% | -67.7% | +258.4% | -64.7% | +594.0% | -94.3% |
| YoY Change | — | — | — | — | -50.8% | -52.6% | +15.1% | +38.9% | +386.9% | +70.3% | +119.0% | -7.5% | +38.4% | +3.7% | -88.5% | -91.6% | -84.8% | -83.5% | +183.5% | -50.1% |